$ANIP
ANI PHARMACEUTICALS INC Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000102302421000007 Filed on March 11, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$57.25M	$208.5M	$47.97M
YoY Change	19.36%	0.93%	-16.03%
Cost Of Revenue	$24.54M	$87.16M	$17.80M
YoY Change	37.87%	38.01%	-11.57%
Gross Profit	$32.71M	$121.3M	$30.17M
YoY Change	8.42%	-15.39%	-18.44%
Gross Profit Margin	57.13%	58.19%	62.9%
Selling, General & Admin	$14.37M	$64.99M	$14.01M
YoY Change	2.57%	16.37%	4.71%
% of Gross Profit	43.93%	53.57%	46.44%
Research & Development	$3.680M	$16.00M	$4.680M
YoY Change	-21.37%	-19.19%	34.48%
% of Gross Profit	11.25%	13.19%	15.51%
Depreciation & Amortization	$10.90M	$44.64M	$9.560M
YoY Change	14.02%	0.06%	10.14%
% of Gross Profit	33.32%	36.79%	31.69%
Operating Expenses	$28.95M	$80.99M	$28.25M
YoY Change	2.48%	7.06%	10.57%
Operating Profit	$331.0K	-$16.02M	-$4.671M
YoY Change	-107.09%	-197.95%	-140.81%
Interest Expense	-$2.550M	-$9.452M	-$2.870M
YoY Change	-11.15%	-27.1%	-20.94%
% of Operating Profit	-770.39%
Other Income/Expense, Net	-$160.0K	-$494.0K	-$110.0K
YoY Change	45.45%	116.67%	-77.08%
Pretax Income	-$2.380M	-$25.96M	-$7.650M
YoY Change	-68.89%	-922.36%	-204.22%
Income Tax	$1.253M	-$3.414M	-$2.817M
% Of Pretax Income
Net Earnings	-$3.635M	-$22.55M	-$4.835M
YoY Change	-24.82%	-470.0%	-189.04%
Net Earnings / Revenue	-6.35%	-10.82%	-10.08%
Basic Earnings Per Share	-$0.30	-$1.88	-$0.41
Diluted Earnings Per Share	-$0.30	-$1.88	-$0.41
COMMON SHARES
Basic Shares Outstanding		11.96M
Diluted Shares Outstanding		11.96M

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.900M	$7.900M	$62.30M
YoY Change	-87.32%	-87.32%	44.88%
Cash & Equivalents	$7.864M	$7.900M	$62.33M
Short-Term Investments
Other Short-Term Assets	$5.900M	$5.900M	$4.000M
YoY Change	47.5%	47.5%	-11.11%
Inventory	$60.80M	$60.80M	$48.16M
Prepaid Expenses	$5.861M		$3.995M
Receivables	$95.79M	$95.80M	$72.13M
Other Receivables	$0.00	$0.00	$1.100M
Total Short-Term Assets	$170.3M	$170.3M	$187.7M
YoY Change	-9.26%	-9.27%	22.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.27M	$41.30M	$40.55M
YoY Change	1.77%	1.72%	6.46%
Goodwill	$3.600M		$3.600M
YoY Change	0.0%		0.56%
Intangibles	$188.5M		$180.4M
YoY Change	4.5%		-10.52%
Long-Term Investments
YoY Change
Other Assets	$802.0K	$57.50M	$1.220M
YoY Change	-34.26%	28.92%	-16.89%
Total Long-Term Assets	$290.9M	$290.9M	$269.1M
YoY Change	8.09%	8.1%	-3.11%
TOTAL ASSETS
Total Short-Term Assets	$170.3M	$170.3M	$187.7M
Total Long-Term Assets	$290.9M	$290.9M	$269.1M
Total Assets	$461.2M	$461.2M	$456.8M
YoY Change	0.96%	0.96%	6.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.26M	$11.30M	$14.61M
YoY Change	-22.9%	-22.6%	64.41%
Accrued Expenses	$2.456M	$22.90M	$2.362M
YoY Change	3.98%	13.93%	38.37%
Deferred Revenue	$100.0K		$500.0K
YoY Change	-80.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.24M	$13.20M	$9.941M
YoY Change	33.22%	33.33%	205.31%
Total Short-Term Liabilities	$78.57M	$78.60M	$61.68M
YoY Change	27.38%	27.39%	-62.74%
LONG-TERM LIABILITIES
Long-Term Debt	$172.4M	$172.4M	$175.8M
YoY Change	-1.91%	-1.93%	161.25%
Other Long-Term Liabilities	$14.48M	$14.50M	$6.514M
YoY Change	122.32%	123.08%	1213.31%
Total Long-Term Liabilities	$186.9M	$186.9M	$182.3M
YoY Change	2.52%	2.52%	168.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$78.57M	$78.60M	$61.68M
Total Long-Term Liabilities	$186.9M	$186.9M	$182.3M
Total Liabilities	$265.5M	$265.5M	$244.0M
YoY Change	8.81%	8.81%	4.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.972M		$17.58M
YoY Change	-128.28%		53.06%
Common Stock	$1.000K		$1.000K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$195.7M	$195.7M	$212.8M
YoY Change
Total Liabilities & Shareholders Equity	$461.2M	$461.2M	$456.8M
YoY Change	0.96%	0.96%	6.08%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$3.635M	-$22.55M	-$4.835M
YoY Change	-24.82%	-470.0%	-189.04%
Depreciation, Depletion And Amortization	$10.90M	$44.64M	$9.560M
YoY Change	14.02%	0.06%	10.14%
Cash From Operating Activities	-$5.710M	$15.27M	$4.800M
YoY Change	-218.96%	-66.54%	-82.37%
INVESTING ACTIVITIES
Capital Expenditures	-$2.110M	$6.135M	-$1.710M
YoY Change	23.39%	-7.54%	71.0%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$10.00K	-$62.19M	$330.0K
YoY Change	-103.03%	197.42%	-45.0%
Cash From Investing Activities	-$2.120M	-$68.32M	-$1.370M
YoY Change	54.74%	148.0%	234.15%
FINANCING ACTIVITIES
Cash Dividend Paid		$0.00
YoY Change
Common Stock Issuance & Retirement, Net		$1.523M
YoY Change		47.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.210M	-1.439M	-770.0K
YoY Change	187.01%	-215.12%	-97.25%
NET CHANGE
Cash From Operating Activities	-5.710M	15.27M	4.800M
Cash From Investing Activities	-2.120M	-68.32M	-1.370M
Cash From Financing Activities	-2.210M	-1.439M	-770.0K
Net Change In Cash	-10.04M	-54.49M	2.660M
YoY Change	-477.44%	-381.88%	-335.4%
FREE CASH FLOW
Cash From Operating Activities	-$5.710M	$15.27M	$4.800M
Capital Expenditures	-$2.110M	$6.135M	-$1.710M
Free Cash Flow	-$3.600M	$9.132M	$6.510M
YoY Change	-155.3%	-76.58%	-76.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001023024
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	anip	Class C Special Stock Value ClassCSpecialStockValue
CY2019Q4	anip	Class C Special Stock Value ClassCSpecialStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	City Area Code CityAreaCode	218
CY2020	dei	Local Phone Number LocalPhoneNumber	634-3500
CY2020	dei	Security12b Title Security12bTitle	Common Stock
CY2020	dei	Trading Symbol TradingSymbol	ANIP
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity File Number EntityFileNumber	001-31812
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Registrant Name EntityRegistrantName	ANI PHARMACEUTICALS, INC
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2301143
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 Main Street West
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Baudette
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	56623
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	316100000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7864000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62332000
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	100328000
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	59946000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	95793000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72129000
CY2020Q4	us-gaap	Inventory Net InventoryNet	60803000
CY2019Q4	us-gaap	Inventory Net InventoryNet	48163000
CY2020Q4	anip	Prepaid Income Taxes Net PrepaidIncomeTaxesNet	0
CY2019Q4	anip	Prepaid Income Taxes Net PrepaidIncomeTaxesNet	1076000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5861000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3995000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	170321000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	187695000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41269000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40551000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5003000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5029000
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	51704000
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	38326000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	188511000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	180388000
CY2020Q4	us-gaap	Goodwill Goodwill	3580000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1220000
CY2020Q4	us-gaap	Assets Assets	461190000
CY2019Q4	us-gaap	Goodwill Goodwill	3580000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	802000
CY2019Q4	us-gaap	Assets Assets	456789000
CY2020Q4	us-gaap	Liabilities Liabilities	265490000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5084000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6231000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3736000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3906000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	172443000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	175808000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14482000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	13243000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9941000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11261000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14606000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2456000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2362000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6407000
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0
CY2020Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	7826000
CY2019Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	8901000
CY2020Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	27155000
CY2019Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	16595000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	451000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78565000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	61676000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6514000
CY2019Q4	us-gaap	Liabilities Liabilities	243998000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	75518
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	15310
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2246000
CY2019Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	723000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	214354000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200800000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4972000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17584000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11437000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4871000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	195700000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	212791000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461190000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	456789000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208475000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206547000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201576000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	87157000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	63154000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	73024000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16001000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19806000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15388000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64986000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	55843000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44063000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44638000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44612000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33742000
CY2020	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	11263000
CY2019	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	6706000
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	446000
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	75000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	224491000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	190196000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	166217000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-16016000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	16351000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	35359000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9452000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12966000
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14758000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-494000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-228000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-550000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25962000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3157000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20051000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3414000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2937000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4557000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.51
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11964000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11841000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11677000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11964000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12040000
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11772000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-6566000
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4492000
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-379000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6566000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4492000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-379000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29114000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1602000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15115000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	174756000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6782000
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	659000
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2978000
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-379000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-1709000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	197263000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9217000
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1031000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5738000
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4492000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	212791000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12936000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1523000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	618000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-6566000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	195700000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	12936000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	9217000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6782000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-13205000
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-9134000
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5180000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44638000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44612000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33742000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3753000
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2324000
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1335000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1876000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7024000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8465000
CY2020	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0
CY2019	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0
CY2018	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	-468000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	445000
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	75000
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23664000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7287000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4743000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2759000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7660000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	379000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1866000
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-403000
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1142000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2294000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5039000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3466000
CY2020	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	1323000
CY2019	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	-3372000
CY2018	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	-3708000
CY2020	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	4982000
CY2019	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-6098000
CY2018	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	6184000
CY2020	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	-1075000
CY2019	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	-73000
CY2018	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	1044000
CY2020	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	10369000
CY2019	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	4043000
CY2018	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	4278000
CY2020	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	2356000
CY2019	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	424000
CY2018	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	968000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15267000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	45631000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	67074000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16467000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	62187000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20914000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5169000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6135000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6635000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5743000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68322000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27549000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27379000
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	8034000
CY2019	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2707000
CY2018	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2813000
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	15000000
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2018	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	7500000
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2020	anip	Proceeds From Lines Of Credit Long Term ProceedsFromLinesOfCreditLongTerm	0
CY2019	anip	Proceeds From Lines Of Credit Long Term ProceedsFromLinesOfCreditLongTerm	118000000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1572000
CY2018	anip	Proceeds From Lines Of Credit Long Term ProceedsFromLinesOfCreditLongTerm	0
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	618000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5738000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2978000
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	118750000
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	26125000
CY2020	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0
CY2019	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0
CY2018	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	375000
CY2020	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	1523000
CY2019	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	1031000
CY2018	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	659000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1439000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1250000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27816000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-54494000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19332000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11879000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67361000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48029000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36150000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12867000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67361000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48029000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62332000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43008000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31144000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5029000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5021000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5006000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67361000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48029000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36150000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7864000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62332000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43008000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5003000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5029000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5021000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12867000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67361000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48029000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6931000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	6092000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	6285000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	4984000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	10033000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	6397000
CY2020	anip	Accrual For Other Investing And Financing Activities AccrualForOtherInvestingAndFinancingActivities	391000
CY2019	anip	Accrual For Other Investing And Financing Activities AccrualForOtherInvestingAndFinancingActivities	500000
CY2018	anip	Accrual For Other Investing And Financing Activities AccrualForOtherInvestingAndFinancingActivities	0
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	172000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	723000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	521000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries, ANIP Acquisition Company and ANI Pharmaceuticals Canada Inc. (together, “ANI,” the “Company,” “we,” “us,” or “our”) is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. ANI was organized as a Delaware corporation in April 2001. At our three facilities, of which two are located in Baudette, Minnesota and one in Oakville, Ontario, we manufacture oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. We also perform contract manufacturing for other pharmaceutical companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 6, 2018, our subsidiary, ANI Pharmaceuticals Canada Inc. (“ANI Canada”), acquired all the issued and outstanding equity interests of WellSpring Pharma Services Inc. (“WellSpring”), a Canadian company that performs contract development and manufacturing of pharmaceutical products. In conjunction with the transaction, we acquired WellSpring’s pharmaceutical manufacturing facility, laboratory, and offices, its current book of commercial business, as well as an organized workforce. </p>
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206547000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201576000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision or benefit, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are subject to risks and uncertainties as a result of the novel coronavirus (“COVID-19”) pandemic. We are unable to predict the impact that the COVID-19 pandemic will have on our future business, financial condition, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">results of operations due to numerous uncertainties. These uncertainties include the occurrence of recurring outbreaks and their severity and the duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. While we experienced a negative impact to our net revenues during the year ended December 31, 2020 in part due to the COVID-19 pandemic, we remain unable to predict the future impact on our estimates and assumptions. There was not a material impact to these estimates or assumptions in our consolidated financial statements as of and for the year ended December 31, 2020. Actual results could differ from those estimates, which may change our estimates in future periods. We continue to closely monitor the impact of the COVID-19 pandemic on our business.</p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Credit Concentration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During the years ended December 31, 2020 and 2019 we had three customers that accounted for 10% or more of net revenues. As of December 31, 2020, accounts receivable from these customers totaled 81% of accounts receivable, net.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">The three customers represent the total percentage of net revenues as follows:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Customer 1</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Customer 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Customer 3</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Vendor Concentration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We source the raw materials for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon our current vendors to supply reliably the API required for ongoing product manufacturing. During the year ended December 31, 2020, we purchased approximately 10% of our inventory from one supplier. As of December 31, 2020, amounts payable to this supplier was $0.9 million. During the year ended December 31, 2019, we purchased approximately 13% of our inventory from one supplier. During the year ended December 31, 2018, we purchased approximately 13% of our inventory from one supplier.</p>
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208475000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206547000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201576000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208475000
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	9900000
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	100000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	100000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000
CY2020Q4	anip	Fdic Guaranteed Amount FdicGuaranteedAmount	250000
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	0
CY2020Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	0
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	400000
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	75000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16000000.0
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19800000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15400000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12800000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9100000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6700000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22548000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	6094000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2019	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-97000
CY2018	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-154000
CY2019	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-97000
CY2018	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-154000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22548000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5997000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15340000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22548000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5997000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15340000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11964000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11841000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11677000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11964000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11841000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11677000
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	103000
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	95000
CY2019	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	96000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11964000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12040000
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11772000
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.51
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4400000
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1300000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3000000.0
CY2020	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Hedge Accounting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At times we use derivative financial instruments to hedge our exposure to interest rate risks. All derivative financial instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheet and are classified as current or non-current based on the scheduled maturity of the instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">When we enter into a hedge arrangement and intend to apply hedge accounting, we formally document the hedge relationship and designate the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. When we determine that a derivative financial instrument qualifies as a cash flow hedge and is effective, the changes in fair value of the instrument are recorded in accumulated other comprehensive (loss)/income, net of tax in our consolidated balance sheets and will be reclassified to earnings when the hedged item affects earnings.</p>
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208475000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206547000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201576000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41269000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40551000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	13468000
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	14911000
CY2018	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	208213000
CY2017	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	188758000
CY2018	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	13287000
CY2017	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3102000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	8847000
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6635000
CY2018	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7170000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5647000
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7002000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	720000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1377000
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1463000
CY2020	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	88000
CY2019	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	191000
CY2018	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	724000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	9479000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	41591000
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	34881000
CY2020Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	3194000
CY2019Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	2902000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	886000
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	361000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	20363000
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	16750000
CY2020Q4	us-gaap	Inventory Gross InventoryGross	66034000
CY2019Q4	us-gaap	Inventory Gross InventoryGross	54894000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5231000
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6731000
CY2020Q4	us-gaap	Inventory Net InventoryNet	60803000
CY2019Q4	us-gaap	Inventory Net InventoryNet	48163000
CY2019Q4	us-gaap	Inventory Write Down InventoryWriteDown	4600000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17527000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12770000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41269000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40551000
CY2020	us-gaap	Depreciation Depreciation	4800000
CY2019	us-gaap	Depreciation Depreciation	4400000
CY2018	us-gaap	Depreciation Depreciation	2100000
CY2020	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000
CY2019	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000
CY2018	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	700000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	58796000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	53321000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019Q4	us-gaap	Goodwill Goodwill	3600000
CY2020Q4	us-gaap	Goodwill Goodwill	3600000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	355170000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	166659000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	307225000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	126837000
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y4M24D
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39900000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40200000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31700000
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	400000
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	75000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	38605000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	35199000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	34451000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	31474000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	28127000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	20655000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	188511000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1700000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1600000
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1400000
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1200000
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	9232000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4985000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	7985000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	559000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1212000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1751000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9791000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6197000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9736000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-14125000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6274000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4630000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	744000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2027000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-556000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	345000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1000000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-214000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-13036000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7301000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5400000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	169000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1833000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-221000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3414000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2937000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4557000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.091
CY2020	anip	Effective Income Tax Rate Reconciliation State And Foreign Income Taxes EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes	-0.073
CY2019	anip	Effective Income Tax Rate Reconciliation State And Foreign Income Taxes EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes	-0.281
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.335
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.265
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.581
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.265
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.025
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.067
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.035
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.131
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.930
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.227
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7174000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8586000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4277000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3750000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	13831000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	7603000
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6101000
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4720000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	21911000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	301000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	172000
CY2020	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	2800000
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14923000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4090000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4767000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2171000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1459000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59555000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45808000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5913000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6029000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	13000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1664000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1008000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7588000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7050000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	263000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	432000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	51704000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	38326000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10500000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	223000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	190000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	66000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	60000
CY2020	us-gaap	Lease Cost LeaseCost	289000
CY2019	us-gaap	Lease Cost LeaseCost	250000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	138000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	97000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	52000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	26000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	319000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18000
CY2020	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	11300000
CY2019	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	6700000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49774000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48470000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52979000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57252000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	57616000
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	59777000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	50177000
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	56921000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7842000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11307000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2802000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	331000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2853000
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1443000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-371000
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1253000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-7011000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-12336000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	434000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-3635000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52887000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54357000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51337000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47966000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	48485000
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	45065000
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	44009000
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	52637000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4402000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	9292000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7328000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4671000
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	469000
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-653000
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2817000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	449000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	6585000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	3895000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-4835000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.55
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2019Q4	anip	Inventory Reserve Charges InventoryReserveCharges	4600000
CY2019Q4	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	6500000

Files In Submission

Name	View Source	Status
0001023024-21-000007-index-headers.html	Edgar Link	pending
0001023024-21-000007-index.html	Edgar Link	pending
0001023024-21-000007.txt	Edgar Link	pending
0001023024-21-000007-xbrl.zip	Edgar Link	pending
anip-20201231.xsd	Edgar Link	pending
anip-20201231ex1020e9a9d.htm	Edgar Link	pending
anip-20201231ex215e26aad.htm	Edgar Link	pending
anip-20201231ex2318a0fdd.htm	Edgar Link	pending
anip-20201231ex311ab6e5c.htm	Edgar Link	pending
anip-20201231ex312e722ef.htm	Edgar Link	pending
anip-20201231ex321a7aacd.htm	Edgar Link	pending
anip-20201231ex418bc77a4.htm	Edgar Link	pending
anip-20201231x10k.htm	Edgar Link	pending
anip-20201231x10k001.jpg	Edgar Link	pending
anip-20201231x10k_htm.xml	Edgar Link	completed
anip-20201231_cal.xml	Edgar Link	unprocessable
anip-20201231_def.xml	Edgar Link	unprocessable
anip-20201231_lab.xml	Edgar Link	unprocessable
anip-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI PHARMACEUTICALS INC Stock $anip

2020 Q4 Form 10-K Financial Statement

#000102302421000007 Filed on March 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI PHARMACEUTICALS INC Stock $anip

2020 Q4 Form 10-K Financial Statement

#000102302421000007 Filed on March 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI PHARMACEUTICALS INC Stock $anip